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ABSTRACT: Lateral flow devices are rapid (and often low cost)
point-of-care diagnosticsthe classic example being the home
pregnancy test. A test line (the stationary phase) is typically
prepared by the physisorption of an antibody, which binds to
analytes/antigens such as viruses, toxins, or hormones. However,
there is no intrinsic requirement for the detection unit to be an
antibody, and incorporating other ligand classes may bring new
functionalities or detection capabilities. To enable other (non-
protein) ligands to be deployed in lateral flow devices, they must be
physiosorbed to the stationary phase as a conjugate, which
currently would be a high-molecular-weight carrier protein, which
requires (challenging) chemoselective modifications and purifica-
tion. Here, we demonstrate that poly(vinylpyrrolidone), PVP, is a
candidate for a polymeric, protein-free test line, owing to its unique balance of water solubility (for printing) and adhesion to the
nitrocellulose stationary phase. End-functionalized PVPs were prepared by RAFT polymerization, and the model capture ligands of
biotin and galactosamine were installed on PVP and subsequently immobilized on nitrocellulose. This polymeric test line was
validated in both flow-through and full lateral flow formats using streptavidin and soybean agglutinin and is the first demonstration of
an “all-polymer” approach for installation of capture units. This work illustrates the potential of polymeric scaffolds as anchoring
agents for small-molecule capture agents in the next generation of robust and modular lateral flow devices and that macromolecular
engineering may provide real benefit.
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■ INTRODUCTION
Lateral flow devices (LFDs) are point-of-care (POC)
diagnostics that are suited to primary care, triage, and
emergency applications.1 The most widely known LFD is the
home pregnancy test, which detects the presence of the
hormone human chorionic gonadotrophin (HCG) in urine in
under 20 min.2,3 In these devices, the stationary phase of the
LFD is nitrocellulose functionalized with an antibody that
binds HCG. Gold nanoparticles (AuNPs) functionalized with
the same antibody are in the mobile phase. This leads to the
sandwiching of HCG between the immobilized antibody on
the device surface and the antibody on the AuNPs, producing
an optical signaloften a red line; notably, other signal
producing elements can be used such as quantum dots,4
graphene oxide,5,6 and carbon nanotubes.7
LFDs have many applications beyond detecting HCG; for
example, they have been deployed for analytes such as drugs of
abuse,8 Ebola virus,9 meningitis,10 and SARS-COV-2.11 The
common design principle shared by the above tests is they all
use antibodies as capture agents (lateral flow immunoassays)
due to the very high affinity and selectivity of antibodies
toward their ligands (in the range of nM to pM). Despite the
ubiquity of antibodies in LFDs, there is no functional
requirement that these be used as the capture agent. There
are examples of LFDs that use protein-anchored nucleotides,12
protein-anchored glycans,13 and lectins14 as capture agents in
the mobile phase and as test lines in the stationary phase.
There are potential benefits of using alternative ligand capture
molecules. For example, Baker et al. have demonstrated that
the spike protein from SARS-COV-2 (causative agent of
COVID-19) can be detected in a lateral flow/flow-through
setup by using N-acetyl neuraminic acid (NeuNAc, a glycan)
as the recognition agent but required a glycosylated protein as
the test line.13 The same system could be deployed in flow-
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through (no test line) to detect COVID-19 positives in
primary patient swab samples.15
Miura et al. have made hybrid LFDs to detect plant proteins,
using glycosylated nanoparticles as the mobile phase but still
using an antibody as the test line.16 By moving away from (or
combining with) antibody-based detection, it may be possible
to more rapidly develop new LFDs, by enabling the
development of fully synthetic systems removing the need to
raise antibodies (in, e.g., animal models). This new approach
could allow for easier manufacture (including scaling) as well
as bringing additional discriminatory power to tests.
Nearly all current LFDs use antibodies (lateral flow
immunoassays) as the stationary phase (as well as the mobile
phase) or use proteins that are functionalized with other
ligands, such as nucleic acids, in the stationary phase. These
approaches lead to three fundamental challenges. First, the
molecular weight of the test-line conjugate must be large
enough to attach to the surface, with absorption ability
decreasing with decreasing molecular weight, limiting scope to
very high-molecular-weight macromolecules.17,18 This limit
can be overcome by increasing the surface area of the
stationary phase membrane, although this limits the choice of
stationary phase membrane material.19 Second, bovine serum
albumin (BSA) or other proteins must be used as “anchors” to
immobilize small capture agents such as nucleotides or glycans
onto the surface of an LFD; this is further limited by the small
number of easy-to-use chemical conjugations available to
functionalize carrier proteins. Moreover, the chemical con-
jugation approaches used do not provide a clear picture of the
number of capture units per protein. For example, when using
glycan-functionalized BSA, a range of degrees of glycosylation
are obtained, with the number of glycans differing by glycan
used too.20 Third, the temperature instability of many protein-
based LFDs above 30−40 °C may prevent devices from being
deployed in various low-resource settings that lack established
health infrastructures and cold chains.21,22 This is especially
problematic, as more expensive lab-based diagnostic techni-
ques are also not applicable, as exemplified by the COVID-19
crisis, creating a clear health inequality between higher- and
lower-income countries.23
When considering test-line design, all test lines used in LFDs
must be sufficiently hydrophobic to remain immobilized on the
surface of the LFD as the mobile phase passes by, but must
also be hydrophilic enough to dissolve in water for application
to the stationary phase (many organic solvents can damage
stationary phase materials). It is also common practice when
designing LFDs to use a series of proteins or polymers such as
bovine serum albumin, casein, or poly(vinylpyrrolidone)
(PVP) as blocking agents (i.e., substances that coat (“block”)
the surface of the stationary phase, to prevent nonspecific
binding of the mobile phase to the stationary phase).17,18
Blocking agents are either applied to the stationary phase as a
pretreatment before the LFD is run or contained within the
buffer of the LFD and run as a component of the mobile phase.
PVP is an interesting case, as it is widely used in LFDs as a
blocking agent, is hydrophilic enough to dissolve in water but
hydrophobic enough to be immobilized onto nitrocellulose
(reflected by vinylpyrrolidone’s logP of ∼0.37),24 is widely
used in biomedical applications,25 and is a synthetic polymer
allowing for chemical modification. Therefore, it seemed an
ideal candidate to prove the principle that a universal
polymeric anchor for LFDs could be discovered.
Herein, we explore the use of capture-agent-functionalized
PVP as a test line in flow-through assays, lateral flow assays,
and lateral flow glycoassays,13 as the first example (to the best
of our knowledge) of creating a synthetic polymer test line.
The performance of the test line was investigated using biotin-
functionalized PVP with streptavidin-functionalized AuNPs (as
the mobile phase) in a flow-through assay as well as free
streptavidin and biotin-functionalized AuNPs in a lateral flow
assay. Further exemplification is provided using glycosylated
PVP to detect a lectin in a lateral flow glycoassay. Crucially, the
polymer molecular weight can be tuned to impact the final
output, providing a unique fine-tuning tool, not possible with
current technologies. The polymer approach is also highly
modular, as shown here. This new approach to immobilizing
Figure 1. Polymer synthesis. (A) Synthesis of MADIX chain-transfer agent (CTA); (B) polymerization of N-vinylpyrrolidone (NVP); (C)
normalized molecular weight distributions from size exclusion chromatography of PVP polymers from Table 1.
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ligands onto the test line will help develop the next generation
of LFDs and simplify workflows.
■ RESULTS AND DISCUSSION
The primary aim of this work was to synthesize and test the
first generation of fully synthetic, protein-free test lines for use
in LFD devices, to facilitate the development pipeline of new
LFDs, using robust polymeric anchoring agents. Poly-
(vinylpyrrolidone), PVP, was chosen as the polymeric anchor,
as it is widely used in LFDs as a blocking agentit is flowed
over the nitrocellulose stationary phase to reduce nonspecific
interactions of analytes or media components. Hence, if it is
blocking nonspecific binding, we reasoned that PVP must be
sufficiently hydrophobic to interact/coat the nitrocellulose
while also being hydrophilic enough to dissolve in water,26,27
which is an essential criterion for test-line printing from
aqueous solution.
Reversible addition−fragmentation chain-transfer (RAFT)
polymerization was employed, as it enables the synthesis of
polymers with defined chain lengths and control over end-
groups (crucial to add the binding ligand of interest).
Furthermore, RAFT or MADIX (macromolecular design by
the interchange of xanthates, a specific type of RAFT) is
compatible with less-activated monomers (LAMs) such as
NVP (N-vinylpyrrolidone) or VAc (vinyl acetate), which are
more challenging than, for example, (meth)acrylates to
polymerize.28−30 A xanthate chain-transfer agent (CTA) of
2-(ethoxycarbonothioylthio)-2-methylpropanoic acid N-hy-
droxysuccinimide ester was designed31 and synthesized with
a N-hydroxysuccinimide (NHS) end-group that could be
substituted by primary amines as shown in Figure 1A.
Displacement of the NHS end-group could also be tracked
using 1H NMR analysis.
Three chain lengths of PVP telechelic homopolymers (DP =
50, 80, and 150) were synthesized (as determined by 1H NMR
end-group analysis) via thermally initiated RAFT polymer-
ization using 4,4′-azobis (4-cyanovaleric acid) (ACVA) as a
radical initiator (Figure 1B). Due to low conversions, which
are typically observed in the polymer synthesis of LAMs,32
monomer to CTA ratios were higher than the target DPs
([M]:[CTA] = 200, 300, and 500) of 50, 80, and 150,
respectively. Polymerization was also stopped at less than
100% conversion to maximize the retention of end-groups. Size
exclusion chromatography (SEC) analysis in DMF with 5 mM
NH4BF4 revealed monomodal molecular weight distribution
peaks with relatively low dispersities (ĐM ≤ 1.7) (Figure 1C
and Table 1).
To determine if PVP provided a suitable anchor, a model
flow-through system was devised using a biotin-end-group,
which has well-characterized and strong binding to streptavidin
to test the capture principle. [Note, flow-through is distinct
from full lateral flow, which has analyte and functionalized gold
particles in the mobile phase, which is evaluated in full later.]
An amino-biotin derivative was synthesized in three steps from
ethylenediamine and biotin following procedures from
Eisenführ et al.33 and Kaufman et al. (Figure 2A).34 A
mono-t-Boc-protected diamine was synthesized (N-Boc-ethyl-
enediamine) and conjugated with biotin. The Boc protecting
group was then removed using TFA to produce “biotin-NH2”,
a biotin derivative with amine functionality.34 The biotin-NH2
was characterized by 1H and 13C NMR, FTIR, and ESI mass
spectrometry (Supporting Information). Functionalization of
the PVP polymers (Figure 2B) was confirmed by the loss of
the NHS protons in the 1H NMR spectra and the addition of
biotin-NH2 protons.
The biotin-functionalized PVP and an unfunctionalized PVP
control were deposited onto the nitrocellulose dipsticks as test
lines, in triplicate, of varying concentrations in water (20, 10,
and 1 mg·mL−1) and then dried at 37 °C. It is noteworthy that
all dipsticks run in this work were run in triplicate, image
analyzed, and the average (mean) taken. A (commercial) gold
nanoparticle (AuNP, 40 nm) functionalized with streptavidin
was flowed down the surface of the dipstick to determine if the
biotin-functionalized PVP sequestered the streptavidin-func-
tionalized particles. As a negative mobile phase, a previously
reported galactosamine-functionalized poly(hydroxyethyl
acrylamide) (PHEA72) gold nanoparticle (16 nm) system
(Gal−PHEA72@AuNP16) was used, which has no affinity to
biotin (Figure 3).13
All dipsticks that used a test line of biotin-functionalized
PVPs successfully bound the streptavidin AuNPs at all
concentrations of the applied test line. Example dipsticks and
the surface image analysis are provided in Figure 4A. Images of
all dipsticks and analysis are provided in the Supporting
Information (Tables S4−S6 and Figures S23−S25). No
nonspecific binding was observed to any of the triplicate
controls at 20 mg·mL−1 (except perhaps weak binding in one
PVP50 test strip to the streptavidin−AuNP40), although a
“bleeding” effect (smearing of the test spot) was observed at
higher test-line concentrations (10 and 20 mg·mL−1),
indicating that the test-line concentration impacts binding
and likely saturates the nitrocellulose membrane (Figure 4B).
Interestingly the best polymer system, i.e., the system that
provided the highest signal response, varied by concentration
of test line applied, although all gave a positive signal in all
triplicates run, with no observable off-target binding to the
unfunctionalized PVP test line seen in the 10 or 1 mg·mL−1
triplicates. This was first determined visually and then
measured by digitally analyzing the image (Figure 4A) and
signal-to-noise ratios determined (Figure 4C). The PVP80−
biotin system had the highest signal response at 10 mg·mL−1
but the lowest at 20 mg·mL−1, while the PVP50−biotin system
had the highest response at just 1 mg·mL−1, while PVP80−
biotin and PVP150−biotin were comparable. This indicates that
the systems produced require tuning to find the correct test
line and concentration for the application; this additional
tunability gained from varying polymer chain length is another
benefit of the polymeric system versus protein-based systems.
Following the successful demonstration of a flow-through
system with biotin-functionalized PVPs as a test line, the next












PVP50 200 22 500 4500 5900 1.33
PVP80 300 33 600 6000 9200 1.47
PVP150 500 55 900 15 100 17 000 1.72
aDetermined from the feed ratio of the monomer to chain-transfer
agent assuming 100% conversion. bCalculated against poly(methyl
methacrylate) standards using 5 mM NH4BF4 in DMF as an eluent.
cDetermined from 1H NMR end-group analysis by comparing the
integrations of the −CH2 signals (δ 2.8 ppm) of the NHS end-group
with those of the corresponding signals of the polymer.
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step was to create a lateral flow setup that sensed for free
streptavidin in solution, which requires biotin-functionalized
AuNPs, coated with a noninteracting water-soluble polymer.
Therefore, a series of biotin-functionalized poly(N-hydrox-
yethyl acrylamide)s (PHEA) were synthesized and immobi-
lized on 16 and 40 nm gold nanoparticles (Figure 5A,B).
PHEA was chosen because of its colloidal stability,35−37
solubility, and its established use to functionalize gold
nanoparticles for lateral flow and flow-through devices.13
Using a pentafluorophenyl-2-dodecylthiocarbonothioylthio)-2-
methylpropanoate (PFP-DMP) chain-transfer agent (CTA)
(see Supporting Information for a detailed synthetic
procedure), a series of PHEA homopolymers were prepared
(DP = 53, 72, 110, as determined by SEC, Figure 5C and
Table 2) according to a previously described protocol.13 Biotin
installation as the end-groups of PHEA homopolymers was
achieved by the reaction of the pentafluorophenol (PFP) end-
group at the α-terminus with biotin-NH2. The functionalized
polymers were characterized by 1H and 19F NMR and FTIR
with successful conjugation of biotin-NH2 confirmed by loss of
the PFP fluorine peaks in 19F NMR. The gold nanoparticles
produced were characterized by UV−vis, DLS (Supporting
Information Figures S13−S22 and Table S3), and X-ray
photoelectron spectroscopy (XPS) (Figure 5D and Supporting
Information Figures S35−S43 and Tables S20 and S21). The
increase in the N 1s/C 1s ratios in the XPS spectra for the
polymer-coated particles and the increased presence of amine
and amide in the C 1s spectra compared to the citrate-
stabilized (“naked”) nanoparticles confirmed the presence of
polymers on the nanoparticles, alongside a shift in the UV−vis
spectra. The library-based design approach to synthesizing
AuNP systems for lateral flow and flow-through assays has
been established by Baker et al.13 as a method to find the
appropriately sized polymer-coated gold particle for the
intended diagnostic application.
The DLS (dynamic light scattering) analysis of the biotin-
functionalized 16 nm gold particles indicated some aggregation
at all polymer lengths. This was observed in the dipsticks, run
in triplicate, where the particles aggregated at the solvent front
and on the PVP test lines even when no analyte and off-target
protein (UEA, Ulex europaeus agglutinin I) at 0.05 mg·mL−1
was present (Supporting Information Tables S7−S9). How-
ever, greater aggregation at the solvent front was observed in
systems containing streptavidin, indicating affinity toward
streptavidin; this was observed visually by more intense
coloration at the solvent front, decreased background along
the strips, and decreased coloration in the wickindicating
that fewer AuNPs passed the solvent front. Note, a PVP test
concentration of 10 mg·mL−1 was chosen to decrease the
bleeding effect observed in the flow-through devices.
The biotin−PHEA-functionalized 40 nm gold particles were
more stable in solution than the 16 nm particles. However,
aggregation at the solvent front and with streptavidin at the
solvent front was observed in the biotin−PHEA72@AuNP40
system but less so in the biotin−PHEA110@AuNP40 system
(Supporting Information Tables S10−12 and Figures S26−
28). Furthermore, off-target binding to the 10 mg·mL−1 PVP−
biotin test lines was observed in all biotin−PHEA110@AuNP40
systems. Hence, the concentration of the test line was
decreased to 1 mg·mL−1. At this concentration, the biotin−
PHEA110@AuNP40 system bound to streptavidin at a protein
concentration of 0.05 mg·mL−1, and this AuNP−analyte
complex was successfully bound by the PVP150−biotin test
line (in all triplicates) with minimal nonspecific binding
observed in the UEA or no analyte system (Figures 6 and 7,
Supporting Information Table 3 and Figure S29). Notably,
aggregation of the AuNP system with streptavidin was
observed at the solvent front likely reducing signal and leading
to increased background in the controls. This experiment
confirmed that functionalized PVP test lines could be used
successfully in LFDs.
To confirm it is the biotin that the streptavidin specifically
binds in the test lines; streptavidin at 0.05 mg·mL−1 with
biotin−PHEA110@AuNP40 particles was tested against biotin-
functionalized and unfunctionalized PVP test lines at a test-line
concentration of 1 mg·mL−1 (Supporting Information Table
S14 and S30). While weak binding was observed to the
unfunctionalized PVP50 test line, binding was far stronger to
Figure 2. Synthesis of biotin-functionalized and galactosamine-functionalized PVP polymers. (A) Synthesis of biotin derivative; (B) synthesis of
biotin-functionalized PVP polymers and galactosamine-functionalized PVP polymers.
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the PVP50−biotin test line and all other biotin-functionalized
test lines versus their unfunctionalized equivalents, with no
binding to the unfunctionalized PVP150 test line observed in
any of the triplicates. It is notable that signal intensity
decreased with PVP chain lengthlikely because relative
biotin concentration on the test line decreases as polymer
chain length increases (as test-line concentration is measured
by mass not molarity), although the decrease in off-target
binding to unfunctionalized PVP150 led to a high signal-to-
noise ratio for the PVP150−biotin system (Figure 7B).
Attempts to use a lower concentration of streptavidin (0.005
mg·mL−1) and the PVP150−biotin test line were unsuccessful,
with a signal-to-noise ratio of ∼1. However, binding to the
PVP80−biotin was observed at this concentration (0.005 mg·
mL−1 streptavidin) versus unfunctionalized PVP80 (signal-to-
noise ratio of >7), likely due to decreased aggregation at the
solvent front between the particles and streptavidin (Figure 7B,
Supporting Information Tables S15 and S31), indicating the
need to tune the AuNP system for the target analyte and test
line used in a finished device.
In comparison to antibody-based lateral flow immunoassays
that often have limits of detection ranging from micrograms to
nanograms per milliliter,38 this system when targeting
streptavidin has a limit of detection (LOD) of ∼0.05−0.005
Figure 3. Schematic of dipstick flow-through assay and example
dipsticks. (A) Design of dipstick; (B) flow-through with biotin-
functionalized PVP test line where streptavidin-functionalized AuNPs
flow and engage the test line, resulting in signal generation; C) flow-
through with unfunctionalized PVP test line where streptavidin-
functionalized AuNPs flow and do not engage the test line, resulting
in no signal generation; (D) flow-through with biotin-functionalized
PVP test line where Gal-functionalized AuNPs flow and do not
engage the test line, resulting in no signal generation; (E) flow-
through with unfunctionalized PVP test line where Gal-functionalized
AuNPs flow and do not engage the test line, resulting in no signal
generation.
Figure 4. Analysis of flow-through dipstick assays. (A) Analysis of
PVP50−biotin and unfunctionalized PVP50 (1 mg·mL−1) versus
streptavidin-functionalized AuNPs and galactosamine-functionalized
AuNPs, with example dipstick of PVP50−biotin versus streptavidin−
AuNP40; (B) representative example dipsticks and graphical
representation of test-line “bleeding” effect at high (top, 20 mg·
mL−1) and lower test-line concentrations (bottom, 1 mg·mL−1); (C)
intensity of PVPx and PVPx−biotin at varying concentrations versus
streptavidin-functionalized AuNP40 (signal-to-noise ratio (PVPx−
biotin intensity/PVPx intensity) is provided in brackets).
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mg·mL−1 or ∼0.8−0.08 nmol·mL−1 for the PVP150−biotin and
PVP80−biotin systems. This is higher than many commercially
available lateral flow immunoassays but is comparable to
commercial pregnancy test LFDs with molar LODs of ∼0.7−
0.07 nmol·mL−1.39
While biotin−streptavidin is an excellent model system, its
low Kd (∼10−14 mol·dm−3)40 is not representative of many
analyte-capture agent scenarios that have lower affinity (higher
Kd). Therefore, soybean agglutinin (SBA), a lectin with a
known affinity for galactosamine, was chosen as an analyte. We
have previously designed and validated an appropriate gold
nanoparticle system (Gal−PHEA72@AuNP16) to sense specif-
ically for SBA in an LFD device using protein agents to
immobilize the glycan to the stationary phase.13 It was
anticipated that the PVP test lines functionalized with
galactosamine may not perform as well as their glycan−BSA
counterpart (Galα1−3Galβ1−4GlcNAc−BSA). This is likely
due to the loss of the cluster glycoside effect (the glycan−BSA
used carried >20 glycans per BSA protein as reported by the
manufacturer) and the use of galactosamine (with free
anomeric position) as the binding glycan in the PVP system.
Initial attempts, in triplicate, to use 20 mg·mL−1 galactos-
amine-functionalized PVPs and an SBA concentration in
solution of 0.05 mg·mL−1 proved unsuccessful with no binding
observed to the SBA (Supporting Information Table S16).
However, no off-target binding was observed to either the no-
lectin, UEA, or unfunctionalized PVP systems (in any test),
which was promising. A higher concentration of SBA (0.5 mg·
mL−1) was therefore chosen for the lateral flow glycoassay
(Supporting Information Table S17 and Figure S32). While
this concentration of SBA did lead to nonspecific binding of
the SBA−particle complex to the unfunctionalized PVP test
line in all cases and in all triplicates; stronger signals were
observed in the PVP150−Gal system (Figure 8), with the
PVP150−Gal system (signal) versus the unfunctionalized
PVP150 system (noise) having a signal-to-noise ratio of 2.44
(Figure 8C). This indicates that the limit of detection (LOD)
of SBA is between ∼0.5−0.05 mg·mL−1. This compares well to
a system using the same nanoparticles in a setup against a test
line of Galα1−3Galβ1−4GlcNAc−BSA (1 mg·mL−1), with an
LOD of ∼0.02 mg·mL−1.41 Considering the PVP does not
(likely) benefit from the cluster glycoside effect to the same
Figure 5. Synthesis of PHEA polymers and AuNPs. (A) Polymerization of N-hydroxyethyl acrylamide (HEA) and postfunctionalization with a
biotin derivative; (B) synthesis of polymer-functionalized AuNPs; (C) normalized size exclusion chromatography analysis of PHEA polymers from
Table 2; (D) C 1s XPS scan of biotin−PHEA72@AuNP40..












PHEA53 28 3800 6600 6000 1.24
PHEA72 40 5100 8900 8600 1.28
PHEA110 70 8600 13 000 14 000 1.27
aDetermined from the feed ratio of the monomer to chain-transfer
agent. bCalculated against poly(methyl methacrylate) standards using
5 mM NH4BF4 in DMF as an eluent.
cDetermined from 1H NMR
end-group analysis by comparing the integrations of the −CH3 signals
(δ 0.92 ppm) of the dodecyl end-group with those of the
corresponding signals of the polymer.
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extent as a multivalent protein surface,42 the LOD achieved is
promising. Although, it is possible that the lectins can bind
multiple PVP chains, depending on their exact orientation on
the surface. Notably, the PVP-based system is not as sensitive
as antibody-based LFDs, such as those for ricin (LOD ≈ 20 ng·
mL−1)43 or a concanavalin A (LOD ∼ 0.1 μg·mL−1),16 but it
does indicate the potential for the integration of polymer
systems into LFDs.
Decreasing the concentration of the PVP test-line systems
was attempted but yielded mixed results (Supporting
Information Tables S18 and 19 and Figures S33 and 34),
indicating that the 20 mg·mL−1 PVP150−Gal system is the
optimum for this particular particle system and analyte.
Interestingly, this is different from the concentration used in
the biotin-functionalized PVP lateral flow system and the
optimum chain length in some of the flow-through assays. This
indicates the need to tune each system depending on the
application, again highlighting the tunability benefits of
polymer chemistry over protein-based systems. Furthermore,
the background could be improved by adjusting the buffer,
tuning the AuNP system, or treating the membrane. Mean-
while, the signal could be improved by printing the test line,
rather than using “by hand” deposition of a test spot or using a
more complex glycan with greater affinity for SBA. These sorts
of modifications were however beyond the scope of this work
that focuses on a proof of concept for polymeric test lines.
■ CONCLUSIONS
Here, the concept of a fully synthetic, protein-free, polymeric
lateral flow test-line is validated and explored for the first time.
It is shown to be a promising alternative to the established
protein-based anchoring reagents. Poly(vinylpyrrolidone),
PVP, was identified as promising immobilization agent, based
on its widespread use as a “blocking agent”, which is
sufficiently hydrophobic to adhere to nitrocellulose stationary
phases but still being water-soluble, which is essential for
Figure 6. Schematic of dipstick lateral flow assay and example
dipsticks. (A) Design of dipstick; (B) lateral flow with biotin-
functionalized PVP test line with no analyte in solution, and biotin−
PHEA-functionalized AuNPs flow and do not engage the test line,
resulting in no signal generation; (C) lateral flow with biotin-
functionalized PVP test line with streptavidin (0.05 mg·mL−1) in
solution, and biotin-functionalized AuNPs flow and do engage the test
line, resulting in signal generation; (D) lateral flow with biotin-
functionalized PVP test line with UEA (0.05 mg·mL−1) in solution,
and biotin-functionalized AuNPs flow and do engage the test line,
resulting in no signal generation.
Figure 7. Analysis of scanned lateral flow strips using test lines of
PVP150−biotin. (A) PVP150−biotin (1 mg·mL−1) versus either no
analyte, streptavidin (0.05 mg·mL−1), or UEA (0.05 mg·mL−1) used
with biotin−PHEA110@AuNP40 (inset example dipstick from
PVP150−biotin versus streptavidin); (B) intensity of PVPx (1 mg·
mL−1) and PVPx−biotin (1 mg·mL−1) versus streptavidin of varying
concentrations using with biotin−PHEA110@AuNP40 (signal-to-noise
ratio (PVPx−biotin intensity/PVPx intensity) is provided in brackets).
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production/printing of the test line. PVP was synthesized by
RAFT/MADIX polymerization using an N-hydroxy-succini-
mide (NHS)-functionalized chain-transfer agent, which
allowed subsequent installation of a glycan or biotin, as a
capture ligand. The polymer anchor was shown to allow
capture in flow-through and lateral flow systems, leading to
specific binding with limited off-target (nonspecific) binding. A
key observation was that the chain length of the PVP (as well
as the concentration applied) was crucial to optimize the signal
generation and specificity. For example, in the flow-through
system when targeting streptavidin-functionalized particles in
the mobile phase, the best PVP−biotin chain length varied
with the concentration of the test line used. Meanwhile, in the
lateral flow system when targeting streptavidin, a 1 mg·mL−1
test line of PVP150−biotin was best, and in the lateral flow
glycoassay, when targeting SBA, a 20 mg·mL−1 PVP150−Gal
test line was best.
We anticipate that the polymeric system discussed (PVP)
could be used as a multifunctional scaffold or platform to
present other capture agents such as short amino acid or
nucleotide sequences and enable a wider range of end-group
functionality beyond amide chemistry (i.e., click chemistry
approaches). The ability to tune the molecular weight of a
polymeric test line will allow further fine-tuning, in contrast to
protein-based anchors. Furthermore, the addition of multi-
valency to the system could also be explored while maintaining
synthetic control over the number of capture agents per
polymer anchor unit. Plus, there exists many thousands of
potential (co)polymer structures, which provide further
opportunities to refine the polymer test-line approach. In
summary, the PVP scaffolds presented and validated here
provide the first examples of a tunable and multifunctional
polymeric test-line capture system for lateral flow devices and




All chemicals were used as supplied unless otherwise stated. N-
Hydroxyethyl acrylamide (97%), 4,4′-azobis(4-cyanovaleric acid)
(ACVA, 98%), 4-(dimethylamino)pyridine (DMAP, >98%), mesity-
lene (reagent grade), triethylamine (TEA, >99%), sodium citrate
tribasic dihydrate (>99%), gold(III) chloride trihydrate (99.9%),
potassium phosphate tri basic (≥98%, reagent grade), N,N′-
diisopropylcarbodiimide (DIC, 99%), 1-vinyl-2-pyrrolidone (≥98.0%
for synthesis), DMSO (ACS reagent, ≥99.9%), deuterated DMSO
(DMSO-d6, ≥99%), deuterium oxide (D2O, 99.9%), deuterated
chloroform (CDCl3, 99.8%), deuterated methanol (CD3OD,
(≥99.8%), diethyl ether (≥99.8%, ACS reagent grade), methanol
(≥99.8%, ACS reagent grade), toluene (≥99.7%,), di-tert-butyl
dicarbonate (≥98.0%), Tween-20 (molecular biology grade),
HEPES, PVP40 (poly(vinylpyrrolidone)400 (average Mw ≈ 40 000),
carbon disulfide (≥99.8%), acetone (≥99%), 1-dodecanethiol
(≥98%), biotin (≥99%, HPLC lyophilized powder), 40 nm gold
nanoparticles (OD1 in citrate buffer), streptavidin−gold (40 nm)
from Streptomyces avidinii, pentafluorophenol (≥99%, reagent plus),
N-hydroxysuccinimide (98%), ethylenediamine (≥99.5%), ethyl
acetate (≥99.5%), trifluoroacetic acid (TFA, ≥99%, reagent plus),
sodium azide (≥99.5%, reagent plus), and potassium permanganate
(≥99%) were purchased from Sigma-Aldrich. Potassium ethyl
xanthate (98%) was purchased from Alfa Aesar. DMF (>99%) and
2-bromo-2-methyl-propionic acid (98%) were purchased from Acros
Organics. Galactosamine HCl and 1-ethyl-3-(3-(dimethylamino)-
propyl)carbodiimide hydrochloride (EDCI, >98%) were purchased
from Carbosynth. Hexane fraction from petrol (lab reagent grade),
DCM (99% lab reagent grade), sodium hydrogen carbonate (≥99%),
ethyl acetate (≥99.7%, analytical reagent grade), sodium chloride
(≥99.5%), calcium chloride, 40−60 petroleum ether (lab reagent
grade), hydrochloric acid (∼37%, analytical grade), glacial acetic acid
Figure 8. Lateral flow strips and analysis using test lines of PVP150−
Gal and PVP150 (20 mg·mL−1). (A) Example lateral flow strips using
test lines of PVP150−Gal and PVP150 (20 mg·mL−1) versus no analyte,
SBA (0.5 mg·mL−1), and UEA (0.5 mg·mL−1), using Gal−PHEA72@
AuNP16; (B) analysis of scanned lateral flow strips using test lines of
PVP150−Gal and PVP150 (20 mg·mL−1) versus either no analyte, SBA
(0.5 mg·mL−1), and UEA (0.5 mg·mL−1); (C) intensity of PVPx (20
mg·mL−1) and PVPx−Gal (20 mg·mL−1) versus SBA (0.5 mg·mL−1)
(signal-to-noise ratio (PVPx−Gal intensity/PVPx intensity) is
provided in brackets).
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(analytical grade) and magnesium sulfate (reagent grade), THF
(HPLC), chloroform (≥99%), Molecular Sieve type 4 Å nominal pore
size (general purpose grade), and 1,4-dioxane (≥99%) were
purchased from Thermo Fisher Scientific. Ethanol absolute was
purchased from VWR International. Nitrocellulose Immunopore RP
90−150 s/4 cm 25 mm was purchased from GE Healthcare. Lateral
flow backing cards, 60 by 301.58 mm (KN-PS1060.45 with KN211
adhesive), were purchased from Kenosha Tapes. Cellulose fiber wick
material, 20 cm by 30 cm by 0.825 mm (290 gsm and 180 mL/min)
(Surewick CFSP223000) was purchased from EMD Millipore.
Soybean agglutinin and Ulex Europaeus Agglutinin I were purchased
from Vector Laboratories. Spectra/Por 7 Dialysis Membrane
Pretreated RC (regenerated cellulose) Tubing MWCO: 1 kDa was
purchased from Spectrum Laboratories. Streptavidin lyophilized was
purchased from Stratech Scientific. Ultrapure water used for buffers
was Milli-Q grade, 18.2 mΩ·cm resistance.
Synthetic Methods
MADIX Agent Synthesis: 2-(Ethoxycarbonothioylthio)-2-
methylpropanoic Acid N-Hydroxysuccinimide Ester
(MADIX1). 10.27g (61.50 mmol) of 2-bromo-2-methyl-propionic
acid was dissolved in 60 mL of ethanol. 15.00 g (93.57 mmol) of
potassium O-ethyl xanthate was added, and the mixture was stirred for
38 h at RTP. The reaction mixture was filtered under gravity, and the
filtrate was diluted with 400 mL of diethyl ether. The organic layer
was washed with water (200 mL × 3), and the aqueous layers were
combined and acidified with 6 M HCl. The aqueous layers were
extracted with diethyl ether (200 mL × 3) and combined with all
organic layers. The solution was dried with MgSO4 and filtered under
gravity. The solvent was removed under vacuum to form a yellow oil.
8.83 g (42.45 mmol) of crude product (2-((ethoxycarbonothioyl)-
thio)-2-methylpropanoic acid) and 9.50 g (82.54 mmol) of N-
hydroxysuccinimide were added to an empty RBF and purged with
nitrogen before 40 mL of anhydrous THF was added; the solution
was then degassed for a further 20 min. The solution was cooled to 0
°C, and 8 mL (9.93 g, 78.65 mmol) of N,N-diisopropyl carbodiimide
was added dropwise over 10 min. The flask was put under positive
nitrogen pressure and stirred for 48 h. The solution was filtered under
gravity, and the filtrate solvent was removed under vacuum. The crude
solid was dissolved in 100 mL of diethyl ether and 100 mL of
saturated NaHCO3 solution. The organic layer was washed with water
(100 mL × 3) and 100 mL of brine once. The organic layer was dried
with MgSO4 and filtered under gravity. The solvent was then removed
from the filtrate under vacuum. The crude product was recrystallized
in ethyl acetate overnight at −8 °C, washed with cold hexane, and
dried to give yellow crystals (25.2%). δH (300 MHz, CDCl3) 4.69
(2H, q, J 7.0, OCH2), 2.85−2.81 (4H, m, C(O)CH2CH2C(O)), 1.76
(6H, s, C(CH3)2), 1.37 (3H, t, J 7.0, CH2CH3). δC (300 MHz,
CDCl3) 208.92 (1C, SC(S)S), 171.43 (1C, OC(O)), 168.82 (2C,
NC(O), 71.00 (1C, OCH2), 52.41 (1C, C(CH3)2), 26.15 (2C, C(O)
CH2CH2C(O)), 25.73 (2C, C(CH3)2), 13.07 (1C, CH2CH3). m/z
calculated as 305.36; found for ESI [M + Na]+ 328.1. FTIR (cm−1)
2989.32 and 2940.46 (methyl or methylene), 1779.80 (ester
carbonyl), 1731.34 (amide), 1462 (methyl), 1202.06 (C=S),
1038.06 (S−C(S)−O).
Representative Polymerization of N-Vinylpyrrolidone
(PVP80). 5.65 mL (5.43 g, 48.88 mmol) of N-vinylpyrrolidone,
0.010 g (0.036 mmol) of ACVA, and 0.0523 g (0.171 mmol) of
MADIX1 were added to 8.5 mL of dioxane and degassed with
nitrogen for 20 min. The reaction was stirred at 80 °C for 3 days. The
solvent was removed under vacuum, and the solid was dialyzed using
0.5−1 kDa cellulose ester tubing in water. The dialyzed product was
freeze-dried overnight to give a white powder. δH (300 MHz, CDCl3)
4.06−3.48 (80H, m, NCH2), 3.47−2.98 (184H, m, NC(O)CH2)
2.85−2.77 (4H, m, C(O)CH2CH2C(O)), 2.58−2.13 (253H, m,
NC(O)CH2), 2.13−1.84 (206H, m, NCH2CH2), 1.84−1.03 (204H,
m, (CH3)2 & NCHCH2 & OCH2CH3). FTIR (cm
−1) 2926 (alkyl
stretch), 1655 (lactam amide), 1422 (CH2).
PVP50 δH (300 MHz, CDCl3) 4.16−3.45 (50H, m, NCH2), 3.51−
2.96 (100H, m, NC(O)CH2) 2.86−2.74 (4H, m, C(O)CH2CH2C-
(O)), 2.71−2.14 (129H, m, NC(O)CH2), 2.14−1.85 (111H, m,
NCH2CH2), 1.85−1.01 (159H, m, (CH3)2 & NCHCH2 &
OCH2CH3).
PVP150 δH (300 MHz, CDCl3) 4.11−3.46 (150H, m, NCH2),
3.46−2.92 (305H, m, NC(O)CH2) 2.85−2.75 (4H, m, C(O)-
CH2CH2C(O)), 2.69−2.12 (428H, m, NC(O)CH2), 2.12−1.84
(320H, m, NCH2CH2), 1.84−1.17 (306H, m, (CH3)2 & NCHCH2
& OCH2CH3).
Representative Poly(N-vinylpyrrolidone) (PVP80) Glycan
Functionalization. 26.6 mg (2.8 μmol) of polymer and 21.2 mg
(0.099 mmol) of galactosamine HCl were dissolved in the minimum
amount of DMSO and 37.5 μL of TEA, stirred for 3 days at RTP, and
dialyzed using 0.5−1 kDa regenerated cellulose membrane tubing in
water. The dialyzed product was freeze-dried overnight to give a pale-
yellow powder (23.5 mg).
δH (300 MHz, CDCl3) 5.35−4.75 (anomeric 1H, m, C(O)OH),
4.04−3.51 (84H, m, CHN & glycan protons), 3.38−2.96 (184H, m,
NCH2 & glycan protons), 2.51−2.11 (176H, m, NC(O)CH2 &
glycan protons), 2.11−1.84 (172H, m, NCH2CH2), 1.84−1.01
(215H, m, (CH3)2 & NCHCH2 & OCH2CH3). FTIR (cm
−1)
2920, 2877 (alkyl stretch) 1655 (lactam amide), 1422 (CH2)
Representative Poly(N-vinylpyrrolidone) (PVP80) Biotin
Functionalization. A 6.5 mg (0.7 μmol) portion of polymer, 5 mg
(17.46 μmol) of amino-functionalised biotin, and 27.5 μL of TEA
were dissolved in the minimum volume of DMSO and stirred at RTP
for 72 h. The reaction mixture was dialyzed using 1 kDa regenerated
cellulose membrane in water and freeze-dried to give a white solid
(5.6 mg). δH (300 MHz, CDCl3) 4.08−3.52 (82H, m, CHN &
C(O)NHCH2), 3.42−2.97 (167H, NCH2, CHCHS, CH2NH2,
CHCHHS, CHCHHS), 2.55−2.12 (226H, NC(O)CH2 & CH2C-
(O)NH), 2.12−1.85 (180H, NCH2CH2), 1.85−1.07 (193H, m,
(CH3) 2 , NCHCH2 , OCH2CH3 , SCHCH 2CH2CH 2 &
SCHCH2CH2CH2). FTIR (cm
−1) 1634 (lactam amide)
Lateral Flow Strip Running Protocol and Analysis
A more detailed summary of dipstick manufacture, running, and analysis
can be found in the Supporting Information, summarized here. Test
lines were added and dried onto the dipsticks; in flow-through, the
analyte was deposited in place of a test line. 50 μL of running buffer
(either with or without analyte) was agitated on a roller for 5 min. 45
μL of running buffer was added to a PCR tube, and a dipstick was
added to the tube, so the dipstick protrudes from the top and the
immobile phase (1 cm from nonwick end) is not below the solvent
line. There was one test per tube, and each test was run for 20 min
before drying at room temperature for 5 min. All tests were run in
triplicate. All strips were scanned and exported to pdf before
conversion to a jpeg file. The jpeg files were analyzed using ImageJ
1.5144 using the plot profile function to create a data set exported to
Microsoft Excel for Mac. The data was exported to Origin 2019 64Bit,
aligned, and averaged (mean). The data was then reduced by number
of groups to 100 data points (nitrocellulose and wick) and plotted as
gray value (scale) vs relative distance along the 100 data points.
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